American Innovation and R&D Competitiveness Act of 2025
Summary
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1990 would restore immediate R&D expensing, directly increasing after-tax cash flow for every R&D-intensive US company by 21% of their R&D spend annually
- 2.Largest absolute beneficiaries are mega-cap tech and pharma with $10B+ R&D budgets: $AMZN, $GOOGL, $MSFT, $AAPL, $NVDA, $MRK, $LLY, $PFE
- 3.Bill is early stage (referred to Ways and Means), has 81 Republican cosponsors, no Senate companion — passage is not imminent and requires significant legislative momentum
Market Implications
A bill restoring immediate R&D expensing is structurally bullish for US R&D-intensive companies. The tax mechanism directly improves free cash flow by allowing companies to deduct R&D costs in Year 1 rather than spreading over 5 years. For $MSFT, $AAPL, and $NVDA — each with $10B-$30B in annual R&D — the cash flow benefit is $2-6B per year. For $AMZN, at $60B R&D, the annual benefit exceeds $12B. The bill is not priced into current valuations because of its early stage; passage would represent a meaningful tax cut for the growth sectors of the US economy. Failure to pass (or prolonged delay) maintains the current amortization regime, which is a headwind for high-R&D companies relative to the pre-2022 tax treatment.
Full Analysis
-
What happened: On March 10, 2025, Rep. Estes (R-KS) introduced HR1990 to restore immediate expensing for qualified R&D costs under IRC §174. The Tax Cuts and Jobs Act of 2017 required R&D costs to be amortized over 5 years (US) or 15 years (foreign) starting in 2022 — this bill would repeal that provision. The bill has 81 cosponsors (all Republicans), was referred to Ways and Means, and has no further action after introduction. It is classified as an early-stage bill with 3 total actions, all on the same day.
-
The money trail: This is a tax expenditure — it reduces federal revenue by the amount of R&D spending companies immediately deduct vs. amortizing over 5 years. HR1990 does not authorize or appropriate any spending; it changes tax treatment. The estimated revenue impact is a reduction in corporate tax receipts equal to 21% of total US business R&D annually (approximately $60-80B/year based on aggregate US R&D spend of $300-400B). This is a DIRECT cash flow benefit to R&D-intensive companies with no procurement or contract mechanism — companies simply pay less tax.
-
Structural winners: The largest US R&D spenders are the direct beneficiaries. By absolute dollar, the winners are: $AMZN (~$60B R&D), $GOOGL (~$45B), $MSFT (~$30B), $AAPL (~$30B), $NVDA (~$12B), $MRK (~$14B), $PFE (~$12B), $LLY (~$11B). By sector, semiconductors, cloud software, biotech/pharma, and industrial innovators ($CAT, $DE, $GE) benefit most. Smaller-cap R&D-intensive companies benefit proportionally more relative to market cap but in smaller absolute dollars.
-
Competitive landscape: HR1990 does not pick winners by sector — it benefits any US corporation with R&D expenses. However, the structural impact favors companies with high R&D-to-revenue ratios (tech, pharma) over asset-heavy, low-R&D sectors (utilities, real estate, consumer staples). For $AMZN and $GOOGL with massive cloud R&D, the bill directly supports margin expansion without requiring top-line growth. For $UNH, the Optum health-tech R&D spend qualifies — a secondary beneficiary.
-
Timeline: HR1990 is at the earliest legislative stage (referred to committee, no hearings yet). Passage probability is low-to-moderate in the 119th Congress given the partisan nature of tax bills and limited cosponsorship (81 total, all Republican). The earliest action would be a Ways and Means markup, then House floor vote, then Senate Finance Committee consideration. Given no companion Senate bill with matching text, the legislative path is long — likely 12-18 months minimum if it gains momentum. Related bills (HR3967, S1639, S2056) show bipartisan interest in R&D expensing but no unified vehicle.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Tax change: immediate expensing for R&D costs vs. current amortization requirement
Who must act
Companies filing US corporate tax returns with R&D expenditures qualifying under IRC §174
What happens
Reduction in taxable income by amount of annual R&D spend, improving after-tax cash flow by 21% of R&D expenses in year incurred
Stock impact
MSFT spent approximately $30B on R&D in FY2025; immediate expensing would reduce tax liability by ~$6.3B annually vs. current 5-year amortization schedule, directly improving free cash flow
What the bill does
Tax change: immediate expensing for R&D costs vs. current amortization requirement
Who must act
Companies filing US corporate tax returns with R&D expenditures qualifying under IRC §174
What happens
Reduction in taxable income by amount of annual R&D spend, improving after-tax cash flow by 21% of R&D expenses in year incurred
Stock impact
AAPL spent approximately $30B on R&D in FY2025; immediate expensing would reduce tax liability by ~$6.3B annually, significantly boosting net income and cash available for buybacks or investment
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Growing and Preserving Innovation in America Act of 2025
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Protecting Health Care and Lowering Costs Act of 2025
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
FISHER SAND & GRAVEL CO: $847M Department of Homeland Security Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Advanced Artificial Intelligence Innovation and Security
This executive order directs multiple federal agencies to prioritize cybersecurity hardening of national security, Department of War, and civilian government systems within 30 days. It establishes a classified benchmarking process for 'covered frontier models' and a voluntary framework for AI developers to provide early access to such models to the government for cybersecurity purposes. It also creates an AI cybersecurity clearinghouse, expands cybersecurity hiring pathways, and directs enforcement against AI-enabled computer crimes.
Further Adjusting the Tariff Regimes for Imports of Aluminum, Steel, and Copper into the United States
This proclamation modifies existing Section 232 tariffs on aluminum, steel, and copper imports by expanding the list of derivative products eligible for a reduced 15% duty to include agricultural equipment and residential HVAC systems, temporarily reducing tariffs on mobile industrial equipment, adding aluminum lithographic plates and steel racks to the derivative tariff coverage, and lowering the threshold for products to qualify as made 'entirely' from American metals from 95% to 85%.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.